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Parasite antigenThe hunt for effective vaccines against the major helminth diseases of humans has yet to bear fruit
despite much effort over several decades. No individual parasite antigen has proved to elicit full protec-
tive immunity, suggesting that combinatorial strategies may be required. Recently it has been discovered
that extracellular vesicles released by parasitic helminths contain multiple potential immune modula-
tors, which could together be targeted by a future vaccine. Increasing knowledge of helminth extracellu-
lar vesicle components, both enclosed by and exposed on the membrane, will open up a new field of
targets for an effective vaccine. This review discusses the interactions between helminth extracellular
vesicles and the immune system discovered thus far, and the advantages of targeting these lipid-
bound packages with a vaccine. In addition, we also comment upon specific antigens that may be the best
targets for an anti-helminth vaccine. In the future, extensive knowledge of the parasites’ full arsenal in
controlling their host may finally provide us with the ideal target for a fully effective vaccine.
 2020 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
1.1. Helminth infection and why we need a vaccine
Helminth infections are widely spread around the globe and
cause a spectrum of neglected tropical diseases. More than 1.5 bil-
lion people, or 24% of the world’s population, are infected with soil-
transmitted helminths alone (Pullan et al., 2014; Jourdan et al.,
2018). In addition, with 142 million people affected by schistoso-
miasis (James et al., 2018) and 87 million by the vector-borne
helminthiases of lymphatic filariasis and onchocerciasis (James
et al., 2018) it is undeniable that helminth parasites are a huge glo-
bal disease burden. Although often overlooked due to a lack of
direct mortalities, it is increasingly recognised that helminth infec-
tion can have many wide-ranging morbidities including anaemia
and growth stunting, cognitive defects, elephantiasis, blindness
and nodding syndrome/epilepsy, and in some cases cancer
(Mostafa et al., 1999; Bethony et al., 2006; Sripa et al., 2007;
Hotez et al., 2008; Shang et al., 2010; Pullan et al., 2014; Johnson
et al., 2017; Pabalan et al., 2018). Infection with helminths affects
the poorest and most deprived communities and is a health chal-
lenge we have yet to solve due to the lack of a vaccine (Hewitsonand Maizels, 2014; Diemert et al., 2018), and the rapid rate of rein-
fection after treatment (Jia et al., 2012).
In addition to human infection, parasitic helminth infection of
farmed animals also causes significant economic losses across the
world and provides the potential for transmission of zoonotic dis-
eases (Robinson and Dalton, 2009; Charlier et al., 2014). Wide-
spread use of anthelmintics in farming has led to the rapid
evolution of drug resistance in some livestock-prevalent species
(Woodgate et al., 2017), suggesting that resistance might also
become a problem for human disease in the not too distant future
(Vercruysse et al., 2011; Sangster et al., 2018). Development of a
vaccine would be the ideal solution as repeated treatments would
not be needed, and if composed of a combination of antigens, the
parasite could not evolve resistance in the same way as to a drug.
Furthermore, vaccines against helminths of livestock with irradi-
ated larvae have proven successful (reviewed by Hewitson and
Maizels (2014)), and the barriers to testing animal vaccines are less
formidable than with humans; hence control of parasites in ani-
mals remains a high priority.
Overall, the pathway to a successful helminth vaccine has
proven difficult to negotiate; many antigens have been identified
in animal models, although typically able to reduce worm bur-
dens by 25–50% rather than achieving sterilising immunity. Few
of these have progressed to evaluation in human trials, which first
require a raft of refinement and regulatory steps to be fulfilled
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may encounter obstacles. The Necator americanus vaccine candi-
date, Ancylostoma Secreted Protein-2 (Na-ASP-2), initially seemed
promising but led to generalised urticarial reactions in some par-
ticipants of a phase 1b trial in a Necator-endemic area, believed
to be due to immunoglobulin E (IgE) against Na-ASP-2 from previ-
ous infections (Diemert et al., 2012). In its place, two further hook-
worm vaccine candidates are being evaluated, glutathione S-
transferase 1 (Na-GST-1), an enzyme found in the blood-feeding
parasite gut involved in detoxification of free heme (Zhan et al.,
2010), and another digestive enzyme, aspartic protease-1 (Na-
APR-1) (Seid et al., 2015). Phase 1 trials have been less problematic
and might lead the way for a combined vaccine formulation
(Diemert et al., 2017). Several candidates for a schistosome vaccine
are also in human trials (Molehin et al., 2016), including the mem-
brane surface proteins tetraspanin (Sm-TSP-2) and calpain (Sm-
p80) (Siddiqui and Siddiqui, 2017), in studies that have recently
been well reviewed (Stutzer et al., 2018).
Parasitic helminths of medical and veterinary concern comprise
two distant phyla; the nematoda (roundworms) and the platy-
helminths (flatworms). The flatworms can further be divided into
cestodes (tapeworms) and trematodes (flukes). The association
between host and parasite is an intimate one, and in many cases
can last for a long time. Hookworms live in the human intestine
between 1 and 3 years for Ancylostoma duodenale and 3–10 years
for Necator americanus (Hoagland and Schad, 1978; Brooker et al.,
2004), although a maximum lifespan of 18 years has been demon-
strated (Beaver, 1988). Some tapeworms can even survive for 20–
30 years (Sandground, 1936). Although nematodes and platy-
helminths are evolutionarily distant, the parasites occupy similar
niches within their hosts and have developed similar methods of
host immune manipulation to ensure long-term survival and to
reproduce abundantly (Maizels and McSorley, 2016).
Host manipulation by helminths is primarily due to the release
of molecules into their environment, broadly referred to as excre-
tory/secretory (ES) products (Lightowlers and Rickard, 1988;
Maizels et al., 2018). These components from parasites are known
to have immunomodulatory properties, for instance ES product
from the model mouse nematode Heligmosomoides polygyrus
(HES) is able to suppress allergic responses (McSorley et al.,
2015), modulate dendritic cells (Segura et al., 2007), and induce
regulatory T cells (Grainger et al., 2010). Similar to many helminth
products, ES products from the trematode Fasciola hepatica skews
the immune response from Th1 to Th2 (Robinson et al., 2013), as
does ES product from the nematode Nippostrongylus brasiliensis
(Balic et al., 2004), and proteins released from schistosome eggs
(Everts et al., 2009), in both cases acting through dendritic cells.
These and many similar studies (reviewed in Harnett (2014);
Maizels et al., 2018) have been accompanied by detailed proteomic
(Ditgen et al., 2014) and glycomic (Hokke and van Diepen, 2017)
analyses of the composition of ES materials, extending also to small
RNAs (Britton et al., 2014), and perhaps most unexpectedly, extra-
cellular vesicles (EVs).
The finding that parasites produce and release EVs was first
demonstrated in the trematode parasites Echinostoma caproni and
F. hepatica (Marcilla et al., 2012). EVs were seen by transmission
electron microscopy (TEM) after ultracentrifugation of ES materials
from both trematodes, and subsequent analysis by mass spectrom-
etry identified 45 and 79 different proteins in these EVs respec-
tively (Marcilla et al., 2012). Nematode and cestode parasite ES
products have also been found to contain EVs (Buck et al., 2014;
Hansen et al., 2015; Zamanian et al., 2015; Tzelos et al., 2016;
Ancarola et al., 2017). Investigation has revealed that EVs are a
common feature of parasite secretions across a wide range of spe-
cies (summarised by Coakley et al. (2015); Eichenberger et al.,
2018b; Tritten and Geary, 2018).1.2. What is under the EV umbrella?
EVs are particles released from a cell that are delimited by a
lipid bilayer, which shields the contents from enzymatic degrada-
tion that would occur in the extracellular environment. Originally,
EVs were identified as large vesicles up to 5000 nm released during
apoptosis, termed apoptotic bodies (Hristov et al., 2004), but it was
subsequently found that healthy cells also release vesicles into
their extracellular environment (Raposo and Stoorvogel, 2013).
Broadly speaking, EVs can be classified into exosomes, ectosomes
(microvesicles/microparticles) and apoptotic bodies according to
their physical appearance, cellular and subcellular origins, and bio-
chemical composition (Fig. 1). Exosomes are 50–100 nm diameter
vesicles that are released by multivesicular late endosome fusion
with the plasma membrane, whereas secreted ectosomes and
microvesicles are 100–1000 nm vesicles that result from direct
outward budding from the plasma membrane (Akers et al., 2013;
Mathieu et al., 2019). Within parasite secretions, EVs the size of
both exosomes and ectosomes have been identified (Cwiklinski
et al., 2015). As it can sometimes be difficult to differentiate the
two from each other, for instance in determining their subcellular
origin specific to each parasite, both have been studied in the con-
text of host-parasite interactions under the umbrella term ‘‘extra-
cellular vesicle”, or EV (Marcilla et al., 2014; Coakley et al., 2015;
Evans-Osses et al., 2015). EV compositional analysis can shed some
light on their biogenesis. As exosomes go through the endosomal
pathway, they are often associated with proteins of the Endosomal
Sorting Complexes Required for Transport (ESCRT) pathway; in
contrast, microvesicles which have directly budded from the
plasma membrane contain many of the same markers as their par-
ental external membrane.
1.3. Helminth EVs – whence?
Whether helminth EVs fall into this neat dichotomy, or are pro-
duced by other routes, remains to be determined. Tracking the
exact site of secretion can be a challenging task, involving TEM
localisation of vesicles and mass spectrometry analysis of their
contents, matching this where possible to the protein profile of a
potential secretion site. In particular, it is important to note a fun-
damental difference between the platyhelminths, with a brush
border-like external lipid-rich membranous tegument, and the
nematodes with an acellular cuticle formed of rigidly cross-
linked collagens and other matrix proteins.
In the case of flatworms such as F. hepatica, the tegument is a
major source of EVs, with a smaller exosome-like population shed
from the tegument of the adult fluke (Cwiklinski et al., 2015; de la
Torre-Escudero et al., 2016), some of which are seen in multivesic-
ular bodies, suggesting a classification as exosomes. EVs are also
released by F. hepatica from specialised cells lining the parasite
gastrodermus (Cwiklinski et al., 2015; de la Torre-Escudero et al.,
2019). Similarly, TEM has shown EVs at the tegument surface of
the trematodes E. caproni, Dicrocoelium dendriticum and of Schisto-
soma mansoni cercariae (Samuelson and Caulfield, 1985; Marcilla
et al., 2012; Bernal et al., 2014; Coakley et al., 2015).
Among the nematodes, the pattern appears to follow secretion
from an internal site before release with fluids through a body
opening. TEM of H. polygyrus adult worm intestine identified vesi-
cle budding of the same size as exosomes, while proteomic analysis
identified a suite of EV components corresponding to worm intesti-
nal proteins on the apical surface of the epithelium. In addition,
Scanning Electron Microscopy (SEM) of the anterior opening of H.
polygyrus visualised structures similar in size to exosomes (Buck
et al., 2014; Coakley et al., 2015). High levels of plasmalogen lipid
components were found in H. polygyrus EVs compared with EVs
from its murine host. While these correlate with an increased
Fig. 1. Overview of specific vesicle biogenesis and secretion pathways. Intra-luminal vesicles (ILVs) are formed within early endosomes via inward budding, retaining
membrane proteins, lipids and other cytosolic contents of the parent cell (1). Endosomes mature to become late endosomes/multivesicular bodies (MVBs) (2) and degrade
their contents via fusion with the lysosome (3) or release their ILVs into the extracellular environment (where they are now classed as ‘‘exosomes”) following fusion with the
plasma membrane (4). Other methods of secretion include ‘budding’ of larger vesicles, such as microparticles, microvesicles and ectosomes, directly from the plasma
membrane (5) or following programmed cellular death, whereby vesicles known as apoptotic bodies ‘‘bleb” from the cellular surface (6). Images are adapted from Servier
Medical Art by Servier (http://smart.servier.com/) and modified by the authors under the following terms: Creative Commons Attribution 3.0 Unported (CC BY 3.0).
Fig. 2. Vesicle release from helminth parasites. Both platyhelminths and nema-
todes have been found to release extracellular vesicles (EVs) from the gastrodermis
(1). In nematodes, EVs released in the intestines may be released into the host via
the anterior (2) or posterior (3) openings. EVs of Brugia malayi have also been found
to be secreted from the excretory/secretory pore (4). In the case of platyhelminths,
EVs can be shed directly from the tegument itself into the surrounding environment
(5). Images are adapted from Servier Medical Art by Servier (http://smart.servier.-
com/) and modified by the authors under the following terms: Creative Commons
Attribution 3.0 Unported (CC BY 3.0).
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cated a specialised source, yet to be localised, at which EVs are
selectively generated (Simbari et al., 2016).
In other studies of nematodes, the ES pore of B. malayi microfi-
lariae was found to be a candidate site for EV release; fluorescent
labelling of a homolog to the ESCRT-associated protein Alix (ALG-
2-interacting protein X), which is used as an exosome marker,
showed staining focused around the pore and its associated duct
(Harischandra et al., 2018). Investigations in Ascaris suum could
not distinguish between EV secretion from the intestinal lining fol-
lowed by exit via the anal pore, or EVs originating from the body
fluid and exiting through the secretory pore, although similarity
of microRNA (miRNA) composition suggests that both sites con-
tribute (Hansen et al., 2019). Indeed, EVs may be released from dif-
ferent sites of a parasite throughout its lifecycle, depending on
what needs to be secreted and the site of interaction with its host
(Fig. 2).
1.4. Helminth EVs – function?
The characterised function of EVs is in intercellular communica-
tion, with regulation of multiple cellular processes including cell
proliferation, survival and transformation (Maas et al., 2017; van
Niel et al., 2018). Vesicles from infectious agents have also been
identified as a means of intra-species communication, with func-
tions being found in protozoan parasites, including species of Plas-
modium and Trypanosoma (Mantel et al., 2013; Wu et al., 2018).
The identification of EVs in helminth parasite secretions therefore
suggests a role in manipulation of the host. There is growing evi-
dence across multiple systems for parasite EV uptake by host cells.
In the case of parasites dwelling in the intestinal tract, EVs from the
trematode E. caproni and the nematode H. polygyrus are inter-
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et al., 2014). Moreover, the intestinal nematode parasites Trichuris
muris and N. brasiliensis both produce EVs which are actively taken
up by mouse colonic and small intestinal organoids, respectively
(Eichenberger et al., 2018a,c). Human cholangiocytes, the cells of
the bile duct epithelium, have been shown to take up EVs secreted
by the liver fluke Opisthorchis viverrini (Chaiyadet et al., 2019).
These cell types are those that would be in direct contact with
the parasitic helminth, so would be close to the site of EV release
in vivo and an ideal target for regulating their surrounding
environment.
Other parasite species, and invasive larvae in the life cycles of
some intestinal parasites, may also target cells of the immune sys-
tem to render an environment favourable to survival. In fact, H.
polygyrus, B. malayi and F. hepatica EVs are all taken up by murine
macrophages (Zamanian et al., 2015; Coakley et al., 2017;
Harischandra et al., 2018; de la Torre-Escudero et al., 2019). EVs
from the tissue-dwelling metacestode stage of Echinococcus granu-
losus are internalised by murine dendritic cells (Nicolao et al.,
2019). This suggests that not only are helminths capable of shaping
their immediate environment via the release of EVs, but the
broader immunological status of their host too.
Across the whole field of EV research, the mechanisms of EV
uptake and cargo delivery into the cytosol of target cells remains
incompletely characterized (Mathieu et al., 2019). The first step
involves targeting the acceptor cell, although whether this requires
a specific combination of proteins or lipids on either the EV surface
or acceptor cell, is unresolved (Mathieu et al., 2019). The internal-
isation of parasite EVs by cell types that engage in active endocy-
tosis for their function, such as macrophages and dendritic cells,Fig. 3. Proposed methods of exosome uptake. Exosomes can generate numerous respo
mechanisms. Exosomes and other vesicles might directly fuse to the plasma membrane o
understood (1). Exosomes might also directly target receptors on the exterior surface o
ligand interactions (2). Exosomes are also known to be taken up by recipient cells by p
receptor or antibody-mediated) (3). From our studies, we showed that antibodies enhan
targeted for lysosomal degradation (4). Alternatively, internalised exosomes and other ve
into the recipient cell cytosol (5). Images are adapted from Servier Medical Art by Servier
Creative Commons Attribution 3.0 Unported (CC BY 3.0).suggest that uptake might be stochastic (Zamanian et al., 2015;
Coakley et al., 2017; Harischandra et al., 2018; Nicolao et al.,
2019). The lack of preference in uptake of EVs from different life
stages of B. malayi by murine macrophages despite differences in
cargo supports this (Harischandra et al., 2018). However, there is
still the possibility that molecules found on the exterior of EVs
might facilitate interaction with specific cell types. Investigation
of surface-exposed lectins on F. hepatica EVs found that they were
distinct from those on the parasites surface and treatment of EVs
with a glycosidase blocked uptake by macrophages (de la Torre-
Escudero et al., 2019).
After contact with target cells, uptake of EVs is believed to occur
through endocytosis, with both clathrin-dependent and indepen-
dent pathways having been reported (Mulcahy et al., 2014;
Zakeri et al., 2018; Mathieu et al., 2019), as shown in Fig. 3. Uptake
of helminth parasite EVs appears to be an active process, as uptake
of T. muris EVs in colonic organoids kept at 4 C did not show inter-
nalization (Eichenberger et al., 2018c). Uptake of EVs from O. viver-
rini by cholangiocytes could be blocked using antiserum to
membrane tetraspanin proteins (Chaiyadet et al., 2019). Brugia
malayi EVs have been found to be taken up bymurine macrophages
via phagocytosis (Harischandra et al., 2018). Cytochalasin D treat-
ment, which inhibits endocytosis and phagocytosis by interfering
with actin polymerisation, prevented the uptake of H. polygyrus
EVs in bone marrow-derived macrophages (Coakley et al., 2017).
Therefore, some form of receptor signalling can be presumed to
be required.
It is speculated that once taken up, parasite EVs can either be
internalized and targeted to the lysosome for degradation or recy-
cled for release back to the extracellular space (Luga et al., 2012;nses in recipient cells, and are suggested to do so through at least three different
f the recipient cell, although the biological pathways involved in this are still poorly
f the recipient cell, driving host responses e.g. by co-stimulation through receptor-
hagocytosis, macro/micropinocytosis or endocytosis (caveolin/clathrin-dependent,
ce uptake of extracellular vesicles (EVs) into recipient cells, which are subsequently
sicles might utilise endosomal escape to release their contents directly or indirectly
(http://smart.servier.com/) and modified by the authors under the following terms:
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parasite EVs could also act at the cell surface without delivery of
their content; during immune responses EVs from dendritic cells
containing Major Histocompatibility Complex (MHC)-peptide
complexes can activate T-cells (Tkach et al., 2017). Many proteins
identified within EVs contain transmembrane domains, so might
have a function on the exterior of the EV in this way. EVs could also
be a means of communication between different individuals of the
same species within a host, or between different parasites in the
same host.1.5. Helminth EVs – the cargo
To understand the function of parasite EVs, it is vital to identify
their contents, which may include proteins, RNA and lipids. Most
data currently available is at the proteomic level, summarised in
a recent review (Mekonnen et al., 2018). In addition, detailed anal-
yses of small RNA profiles in EVs have been carried out for some
species (Buck et al., 2014; Zamanian et al., 2015; Zhu et al.,
2016). A specific nematode argonaute protein has been found that
is delivered with small interfering RNAs (siRNAs), suggested to
provide selectivity in small RNA packaging into EVs, although it
might also play a role in facilitating endogenous gene regulation
in the host after uptake (Chow et al., 2019).
Not only can proteins and RNAs be packaged in exosomes in
order to have an effect on the host, EVs are also a means of lipid
transport between cells, and they are known to transport free fatty
acids and prostaglandins, as well as enzymes involved in their syn-
thesis (Subra et al., 2010). EVs carrying bioactive lipids are impor-
tant in immune system function (Sagini et al., 2018). Schistosoma
mansoni lipids have been identified that activate eosinophils
(Magalhaes et al., 2018) and it has been argued that an effective
way for this lipid delivery to occur could be via EVs (Coakley
et al., 2019).
EV contents may change throughout a parasite’s lifecycle. Anal-
ysis of mRNA found in EVs from different life stages of Haemonchus
contortus suggest that the gut is the likely source of vesicle-
associated miRNAs in the L4 stage but not in the adult worm (Gu
et al., 2017). EVs from B. malayi are produced across all stages of
the lifecycle, right through from microfilariae to adult male and
female worms (Harischandra et al., 2018), although EVs are most
abundantly released from L3s, with a lower concentration in adult
secretions (Zamanian et al., 2015). Ascaria suum contains more
unique miRNAs in L3 and L4 EVs compared with adult-produced
EVs (Hansen et al., 2019). These differences may be due to L3s
needing to manipulate the host much more during migration
through different tissues, compared with adults that have fixed
residence in the lymphatics and small intestine respectively.
Harischandra et al. (2018) found that the EV proteome of B.
malayi is both stage- and sex-specific, with 74 proteins identified
in female EVs compared with only 20 for male worms
(Harischandra et al., 2018). This is similar to the ES products of B.
malayi that are already known, where female parasites secrete a
greater number of proteins, and in greater amounts, than male
worms (Moreno and Geary, 2008; Bennuru et al., 2009). Proteins
with putative immunomodulatory functions, such as BmMIF-1,
were enriched in the female worm EV profile, suggesting a more
immunomodulatory role (Harischandra et al., 2018). Perhaps the
close association of males and females in the lymphatic duct ren-
ders the production of these proteins by the males obsolete.2. Immunosuppression by helminth EVs
The contents of parasite EVs, such as small RNAs matching host
targets, and uptake by immune cells, suggest some role inimmunomodulation of their respective hosts. Indeed, there is
growing evidence that uptake of EVs from helminth parasites leads
to downregulation of immune responses. Examples of this are pre-
sented in Table 1. The majority of uptake and effects reported so far
are for innate immune cells; mainly macrophages, which tend to
uptake extracellular contents (Wang et al., 2015; Zamanian et al.,
2015; Coakley et al., 2017). It is interesting to see EV effects on cells
that are directly in contact with the parasite itself. Investigation of
the effect of O. viverrini EVs on human cholangiocytes found that
they drove cell proliferation and induced changes in proteins asso-
ciated with cancer pathways, suggesting a contribution to the
development of cholangiocarcinoma in liver fluke-infected
patients (Chaiyadet et al., 2015). Uptake by epithelial cells has been
proven (Buck et al., 2014; Eichenberger et al., 2018a,c), and Buck
et al. (2014) found downregulation of genes by EVs in a mouse
epithelial cell line, including a regulator of MAPK signalling and a
subunit of the IL-33 receptor. Investigation of a wider range of cell
types may help to explain more of the pathological sequelae of hel-
minth parasite infection.
There are proteins present within parasite-produced EVs that
have already been characterised as immunomodulators, or with
similarity to known immunomodulators. An example of this is
the H. polygyrus protein Transforming growth factor (TGF)-b
mimic, or TGM (Johnston et al., 2017). TGM was originally identi-
fied in H. polygyrus ES products as able to interact with TGF-b
receptors and induce Foxp3+ T-regulatory (Treg) cells, which can
then suppress effector T-cells (Johnston et al., 2017). A whole fam-
ily of these molecules has since been identified, including nine fur-
ther members, with five produced by the adult parasite and four by
the larval stage (Smyth et al., 2018). TGM is present in H. polygyrus
EVs (Buck et al., 2014), as well as in a soluble form that is known to
potently drive Treg differentiation (Johnston et al., 2017). It
remains to be determined whether vesicle-bound TGM is a more
effective form of delivery that may target a wider variety of cells,
and/or remain active once taken up in vesicles by host cells.
EVs from the nematode Trichinella spiralis are able to elevate
production of IL-10 and IL-6 in peripheral blood mononuclear cells
(Kosanovic et al., 2019). These EVs contain proteins recognised by
the monoclonal antibody 7C2C5, which are already known to have
modulatory effects on dendritic cells, translating to induction of IL-
4 and IL-10 from T-cells (Cvetkovic et al., 2016). B. malayi EVs con-
tain miRNAs with homology to human miRNAs, suggesting target-
ing of host genes (Zamanian et al., 2015). This includes the miRNA
Bma-let-7 which is involved in both innate and adaptive responses
to infection (Jiang, 2018). A homologue of let-7 has also been iden-
tified in H. polygyrus EVs, suggesting conservation of this method of
immunomodulation across nematodes (Buck et al., 2014). EVs from
both nematodes (B. malayi, Teladorsagia circumcincta) and platy-
helminths (F. hepatica, E. caproni) contain thioredoxin peroxidases
(peroxiredoxins) (Marcilla et al., 2012; Cwiklinski et al., 2015;
Tzelos et al., 2016; Harischandra et al., 2018). These are proposed
to be able to modulate the host immune response, including induc-
ing development of a Th2 response via alternative activation of
macrophages (Robinson et al., 2010). In addition, B. malayi EVs also
contain macrophage migration inhibitory factor (MIF)
(Harischandra et al., 2018), which can act in the same way as
mouse-produced MIF to promote alternative activation of macro-
phages (Prieto-Lafuente et al., 2009). There is therefore a growing
body of knowledge that EVs themselves represent a complex pack-
age of immunomodulators, with the vesicular structure possibly
protecting the proteins within until they reach the cell in which
they exert their action.
Targeting EVs to develop a vaccine against helminths is there-
fore a rational strategy to disable the immunomodulatory effects
of the vesicles, while also priming the host immune system to
detect the presence of live parasites through their release of EVs.
Table 1
Immunological effects of helminth extracellular vesicles (EVs), in vitro and in vivo.
Parasite Model used Cell type Action Protein/RNA responsible Reference
Echinococcus granulosus
(cestode)
BMDC stimulation Murine dendritic cells EVs are internalised and induce maturation (CD86
upregulation)
EV proteins identified but not tested (Nicolao et al., 2019)
Brugia malayi (nematode) J774A.1 macrophage
cell line
Murine macrophages EVs are internalised and induce classically activated
phenotype (increased G-CSF, MCP-1, IL-6 and MIP-2)




(BMDM) and RAW cell
line
Murine macrophages EVs suppressed alternative and classical activation of
macrophages. Suppress ST2/IL33R expression
Not investigated (Coakley et al., 2017)
Alternaria fungal




Reduction in lung eosinophilia, suppression of IL-5 and
IL-13 in ILCs. IL-33R/ST2 suppression
Proteins and RNA identified (Buck et al., 2014)
MODE-K mouse cells Intestinal epithelial
cells
Dusp1 and IL-33R downregulation (MAPK signal
regulator, IL-33 receptor)





Colon tissue EVs reduce proinflammatory cytokines IL-1b, IL-6, IL-
17A and IFNc. Increase in anti-inflammatory IL-10






PBMC stimulation PBMC EVs elevate IL-6 and IL-10 production, non-significant
decrease of IL-17A
Not investigated, but EVs contain immuno-
modulatory proteins identified in T. spiralis ES,
recognised by 7C2C5 antibody
(Kosanovic et al., 2019)
Echinostoma caproni (trematode) Subcutaneous injection Spleen Induction of IL-4, IFNc and TGF-b suggestive of Th2/Treg
phenotype
Not investigated (Trelis et al., 2016)
Fasciola hepatica (trematode) DSS-induced colitis in
mice
Not mediated by B- or
T-cells (carried out in
Rag1-/- mice)
EVs reduce proinflammatory cytokines TNF and IL-6,
suppress neutrophil infiltration, decrease COX-2, NFjB
and phosphorylation of p38 MAPK





Human cholangiocyte EVs promote cell proliferation and stimulate wound
healing and tumorigenic pathways. IL-6 secretion





Murine macrophages Increased iNOS by qRT-PCR, increased TNF by qRT-PCR
and ELISA Increase in surface CD16/32 by flow cytometry
– skew to M1 polarisation
Not investigated (Wang et al., 2015)













C. Drurey et al. / International Journal for Parasitology 50 (2020) 623–633 629Together, these effects seem likely to boost the immune system of
the host in its efforts to clear worm infections.3. Antibody interactions with EVs
Most successful vaccines act by inducing a neutralising anti-
body response, and protective immunity against most helminth
parasites has been shown to be antibody-dependent (Hewitson
and Maizels, 2014). Hence, in developing and evaluating a poten-
tial vaccine, a key parameter is generation of a potent antibody
response. However, in contrast to subunit vaccines representing
individual antigenic proteins, EVs present a much more complex
target which may or may not offer accessible epitopes for an
antibody-based vaccine strategy. In addition to the issue of
whether suitable exposed antigens are present on EVs, questions
are also posed of whether antibody interactions with EVs can effec-
tively neutralise their biological functions and if such neutralisa-
tion is sufficient to lead to robust protection against infection
with helminth parasites.
Evidence to date indicates that, in fact, immune recognition and
neutralisation of EVs does result in significant protective immu-
nity. Whole EVs have been used as vaccines with varying levels
of success (see Table 2), ranging from nearly full clearance
(Coakley et al., 2017) through to a more modest effect in reduction
of egg burden (Trelis et al., 2016). Shears et al. (2018) found that
EVs had to be intact to have an effect, suggesting that the configu-
ration of immunogenic proteins, how they function and how they
are displayed during a response, will have implications for a suc-
cessful vaccine response.
Since the EVs themselves are not live pathogens, this outcome
indicates that immunity acts by blocking EV functions such as
entry into host cells, or access to target compartments within those
cells, both outcomes consistent with an antibody-dependent path-
way. Interestingly, in the case of H. polygyrus EVs, antibodies actu-
ally increase their uptake by macrophages. However, macrophages
taking up EVs through the antibody-dependent pathway were pro-
tected from EV-mediated inhibition of activation (Coakley et al.,
2017). Rather than accessing the host cell cytoplasm, antibody-
treated EVs were directed into a degradative lysosomal pathway,
thereby limiting their immunomodulatory functions (Coakley
et al., 2017). Whilst enhanced EV uptake has also been shown in
macrophages exposed to either F. hepatica EV antibodies or
infected host serum, the authors of this study suggest that someTable 2









with EVs + alum i.p.






with EVs no adjuvant
subcutaneously
Vaccination deceased worm burden by







with EVs no adjuvant
subcutaneously
No difference in worm burden seen.
Vaccination decreased EPG by ~60%. Dela
in parasite development. Increase in






EVs + alum i.p.
Vaccination decreased worm burden by
27%, EPG reduced by 32%. Average length
of worms shorter
HES, Heligmosomoides polygyrus excretory/secretory products; EPG, eggs per gram.specific cargo such as helminth defence molecule (HDM) and
cathepsin L1 could potentially circumvent the lysosomal pathway
and actually retain their modulatory function (de la Torre-
Escudero et al., 2019).
In other systems such as O. viverrini, the role of antibodies
appears to involve the inhibition of uptake, indicating that key epi-
topes are associated with the attachment and invasion process of
the EVs (Chaiyadet et al., 2019). Although a different mechanism
to directed lysosomal degradation, the net effect is similar, fore-
stalling the ability of EVs to down-modulate host immunity. The
contrast might be in the cell type targeted by EVs of different par-
asites, with H. polygyrus affecting macrophages which express Fc
receptors, while O. viverrini interacts with cholangiocytes of the
bile duct which probably do not.
A less explored question is whether, in helminth infections, the
host naturally generates an antibody response to EVs and, if so,
whether this contributes to acquired immunity to infection. Cer-
tainly, some EV antigens are immunogenic and in the case of ces-
tode EVs (from E. multilocularis and Taenia crassiceps) include a
range of conserved antigens known to have immunodiagnostic
value, such as endophilin/p29, FABP, 14-3-3, Em18/H17g and
Ts8B1 (Ancarola et al., 2017). Hence, in these infections at least,
EVs must also be taken up by competent antigen-presenting cells
for processing and activation of the adaptive immune response.4. Vaccine antigens
Although vaccination with native EVs isolated from helminth ES
products has served as a useful proof of concept, it will not be fea-
sible to scale up as a clinical vaccine for general use. In addition, it
will be important to define vaccine target molecules to evaluate
efficacy of antibody generation in different populations, to research
possible antigenic variation in parasite isolates, and to monitor any
future loss of protection. For these reasons, attention is now turn-
ing to identifying and testing specific EV-associated antigens which
can be formulated into a vaccine that recapitulates the protective
action of vaccination with whole EVs.
In principle, the EV represents a large membranous surface
which envelops a relatively small intravesicular volume (Buzas
et al., 2018); it is to be expected therefore that a high proportion
of EV-associated proteins will be linked to the vesicular membrane,
although one cannot necessarily predict which may be exposed on
the exterior surface. In mammalian EVs, several hundredAntibodies Reference
Exosomes elicited IgM, IgG1, IgA and IgE isotypes
reactive with EVs. Mice vaccinated with HES or HES
supernatant also generated EV-responsive IgM. Sera
from EV-vaccinated mice contained both IgM and
IgG1 reactive reactive to HES and HES supernatant
(Coakley et al.,
2017)
Vaccination boosted IgG1 and IgG2a/c serum
antibody responses to ES depleted of EVs. Range of
IgG antibodies in sera against EV components 50–
200 kDa in size. Possible targets identified
(Shears et al., 2018)
y
Exosomes elicited significant IgM and IgG response
in serum. IgG1, 2b and 3 subtypes responsible for IgG
increase. Antibodies against exosome/ESP
components mainly 90 kDa in size. Bands the same
for immunisation with exosomes and infected
animals. Possible targets identified
(Trelis et al., 2016)
Sera showed increase in IgG against EVs both pre and
post challenge. Antibodies from vaccinated hamsters
blocked uptake of EVs by cholangiocytes
(Chaiyadet et al.,
2019)
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served proteins such as tetraspanins (CD9, CD63 and CD81) with
two extracellular loops separated by four transmembrane seg-
ments, as well as proteins involved in cell adhesion, and a variety
of ectoenzymes, any or all of which may be required for the process
of target cell entry. While some EV surface components are integral
membrane proteins, others may be tethered by those membrane
proteins, as for example in TGF-b attached to the betaglycan recep-
tor (TbRIII) on cancer exosomes (Webber et al., 2010).
Many similar proteins have been identified in helminth EVs.
Tetraspanins appear to be a defining feature of both host and par-
asite EVs (Andreu and Yanez-Mo, 2014), and notably had been
flagged as potential vaccine antigens in a number of earlier studies.
In S. mansoni, both TSP-1 and TSP-2 induce a protective response in
mouse models, TSP-2 more so, and this protein also elicited strong
antibody responses in exposed but uninfected residents of an
endemic area in Brazil (Tran et al., 2006). Sm-TSP-2 has been fur-
ther developed as a lead candidate for a human S. mansoni vaccine
(Cheng et al., 2013). However, in Schistosoma japonicum, TSP-2 was
less effective and showed considerable polymorphic variation
between isolates, potentially limiting its application as a vaccine
target (Zhang et al., 2011). Seven TSP proteins from E. multilocularis
have also been tested in a mouse model, using the larger extracel-
lular loop, with encouraging results in particular for Em-TSP-3
(Dang et al., 2009, 2012). Similarly, TSP from the human filarial
nematode B. malayi showed protective effect in a mouse model
(Dakshinamoorthy et al., 2013). However, tetraspanins are also
found on the external surface of each of these parasites, and hence
it is not established whether TSP vaccination acts primarily against
EVs, or directly against the worms themselves.
As well as conserved and probably functionally essential com-
ponents such as tetraspanins, EVs contain a suite of products
derived from their parental cells. In the case of H. polygyrus EVs,
many proteins associated with the apical membrane of the nema-
tode intestinal tract were identified; electron microscopy also visu-
alised vesicular bodies in the lumen of the worm gut, and some
multi-vesicular bodies in the underlying tissue (Buck et al.,
2014). In addition, EVs from this parasite contained ectoenzymes
such as the metalloproteases (MEPs) and H11 (Buck et al., 2014).
Heligmosomoides polygyrus is closely related to the trichostrongy-
loid parasites of sheep such as Haemonchus contortus (the barber’s
pole worm), and it is striking that H11 and MEPs have been studied
for many years as leading vaccine antigens against this parasite
(Andrews et al., 1995; Newton et al., 1995); indeed a H11/MEP
combination is now commercially available as ‘‘Barbervax” and is
comprised of native membrane glycoproteins purified from para-
site extracts that is effective in sheep (Smith et al., 2001). Although
classically, the mode of action has been assumed to be antibody
interference with intestinal function in the worm, the possibility
should now be considered that vaccine-induced antibodies block
EVs from this parasite from executing their immunomodulatory
function.
Whilst treatment with Barbervax is shown to confer protection
against H. contortus infection, it fails to elicit a long-term memory
response. As H11 and MEPs are parasite gut antigens, they are lar-
gely ‘‘hidden” from the host during infection and fail to induce nat-
ural immunity, thus frequent vaccination boosts might be required
in order to maintain protection. This is an important consideration
when developing future helminth vaccines that may utilise EV-
associated antigens. Ideally, vaccines which are generated against
either molecules exposed on the EV surface, or EV-derived epitopes
which have been processed and presented during an adaptive
immune response may have a greater chance of long-term protec-
tive responses in endemic areas.
To date, there has been little systematic research into the mode
of action of EV-associated proteins. Many important issues shouldbe addressed, in particular the relation of each different stage of
parasite to the target antigen, establishing for example if a vaccine
would act on immature or migratory larvae, or only on the mature
adult stage. The question of EV heterogeneity also remains to be
investigated, as it is currently unknown if expression of each vac-
cine antigen is universal, and if not, whether subsets of EVs that
escape immune attack can still act in an immunomodulatory fash-
ion. Finally, if conserved EV antigens are to be targeted, caution is
required where similar proteins are also expressed in the mam-
malian host in the event that vaccination would interfere with host
physiological processes, or indeed prompt an autoimmune
response.5. Vaccine delivery
In parallel with identifying effective helminth antigens, it is also
important to consider their means of delivery for future vaccines.
In fact, extracellular vesicles may have intrinsic properties that
promote immune responses, as in the case of outer membrane
vesicles from Gram-negative bacteria that present multiple Toll-
like receptor (TLR) ligands for innate immune activation (Tan
et al., 2018). Vesicles can be loaded with exogenous antigens, or
harvested from bacteria expressing recombinant parasite proteins;
where antigens are encapsulated within the lipid bilayer, they
would be protected from degradation in the extracellular space,
might be released in a measured fashion over time, thereby max-
imising immunogenicity. As well as manipulated EVs, it is also pos-
sible to create synthetic liposomes as both antigen and adjuvant
carriers (Nisini et al., 2018), and as recently reported, a recombi-
nant E. granulosus antigen/liposome complex stimulated protective
immunity of 95% in mice (ZongJi et al., 2019).
Mammalian-derived exosomes also pay critical roles in immune
regulation and activation (Thery et al., 2009), with dendritic cell
(DC)- and tumour-derived exosomes found to induce eradication
of tumours (Syn et al., 2017). Exosomes from DCs pulsed with Tox-
oplasma gondii-derived antigens were able to produce protective
responses against infection and congenital toxoplasmosis in mice
(Beauvillain et al., 2007, 2009), showing that this method might
also be effective for parasites. The success of using exosomes
derived from DCs is believed to be due to the presence of functional
MHC class I and II and T-cell costimulatory molecules on their sur-
face which can display antigen to the immune system (Thery et al.,
2002). Some form of antigen presentation via a receptor on the sur-
face may therefore be required for an EV-based helminth vaccine
to be successful. Another important consideration in utilising DC-
derived EVs is the heterogeneity of the vesicles produced, as Wah-
lund and colleagues were able to demonstrate distinct differences
in the antigen processing and immunostimulatory capacity of
microvesicles and exosomes in vivo (Wahlund et al., 2017). Direc-
ted targeting of an antigen to the exosome surface has been found
to improve immunogenicity of adenoviral vaccines in mice (Bliss
et al., 2020), so a more convenient means of vaccination could be
to drive the host to secrete the antigens within its own EVs, rather
than manufacturing EVs with the correct configurations for antigen
presentation.
Packaging into vesicles also makes mucosal delivery of the anti-
gen possible, as lipid-based particles can protect the contents from
degradation (Corthesy and Bioley, 2018). Mucosal delivery has
been found to be more effective at inducing antigen-specific
immune responses at mucosal surfaces and is found to be just as
effective as parenteral administration at inducing systemic
immune responses (Lycke, 2012). This would be ideal in combat-
ting helminth infection, which often takes place at or involves
mucosal sites. Oral vaccination using a N. americanus lipopeptide
in both nanoparticles or packaged in liposomes has been demon-
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et al., 2020). Mucosal vaccination, for instance through oral or
nasal routes, would also offer the advantage of ease of administra-
tion, making mass vaccination possible in the least developed and
developing countries where these helminth infections are
endemic.
6. Concluding remarks
The possibility of using EVs, and EV antigens, as novel helminth
vaccines is a new and exciting entrant into the field of parasitology.
As discussed above, a myriad of possibilities now need to be
explored, ranging from the identification of individual antigens,
the elucidation of mode of action, and the optimisation of vaccina-
tion regimens. We have as yet little information on how best to
present EV antigens, or indeed how best to express them or accom-
pany themwith the most suitable adjuvant, and still no insight into
the most effective mode of immune response that a vaccine would
seek to induce. However, much progress continues to be made at
the more empirical level, validating choice of key antigens and pro-
viding proof-of-principle for the global approach is now under
way. We look forward to many more incisive findings in both
detailed reductionist analysis, and system-wide immune outcomes
that may together deliver a ground breaking vaccine strategy for
helminth diseases.
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